Another twist in the EU parallel trade saga?

The free movement of goods across Europe might be beneficial for some, but for pharmaceutical companies, the parallel trade of medicines is not welcomed, and is viewed as a system that can damage patient safety and innovation. Could recent shifts in government policy, however, signal a change in favour of pharma?
Jan 01, 2010
Volume 22, Issue 1